Studies in vitro and in vivo were conducted to investigate the effect of pilocarpine on ocular absorption of levobunolol when both drugs were formulated in one solution dosage. The ocular absorption of levobunolol is pH-dependent. Due to the large buffering capacity of pilocarpine at pH 5.5, the ocular absorption of levobunolol from pilocarpine-containing solutions was reduced by approximately four-fold as compared to a non-pilocarpinecontaining formulation at pH 7.2. The ocular absorption of levobunolol in the presence of pilocarpine at acidic pH was enhanced by the use of sulfosuccinates, specifically Schercopol CMS.
INTRODUCTION
In many patients, the disease of glaucoma is manifested by elevated intraocular pressure. The present treatment of glaucoma focuses on lowering the IOP to levels that might not produce further damages to the optic nerve head and deterioration of the visual field. Efforts in lowering the IOP involve the use of pharmacological agents that reduce the aqueous humor formation (e.g., ß-adrenergic antagonists) or enhance aqueous humor outflow (e.g., muscarinic agonists). Many patients require the concomitant use of drugs from more than one pharmacologie class in order to achieve the desired decrease in IOP.
Levobunolol, a ß-adrenergic antagonist, and pilocarpine, a muscarinic agonist, when used individually have been efficacious in lowering the IOP in glaucomatous patients. They are also prescribed as concomitant therapy in an attempt to lower the IOP to a greater extent in some patients. To address such a need, efforts were expended to evaluate potential interactions between levobunolol and pilocarpine when both drugs were formulated into one ophthalmic solution dosage. A single ophthalmic dosage form will improve patient compliance while achieving the therapeutic endpoint, pressure control.
Both ocular levobunolol and pilocarpine are rapidly absorbed when administered individually. After an eyedrop instillation, levobunolol concentration in the aqueous humor rose quickly and reached the maximum within 30 minutes post-dosing (1) (2) (3) . The formation of its major metabolite dihydrobunolol in the cornea was pH-dependent and capacity-limited (3) . However, the effect of formulation pH on the ocular absorption of levobunolol has not been reported. The The ocular absorption of levobunolol and pilocarpine from additional formulations, LP5.5 fortified with 0.2%, 0.5%, and 1.5% (w/v) Schercopol-CMS, were also evaluated.
Ocular Absorption of Levobunolol InVivo:
Rabbits were randomly divided into groups of fifteen. All animals received one eyedrop (50 ul) instillation in the left eye. The ophthalmic solutions used were 0.5% levobunolol HCl/2% pilocarpine HC1 at pH 5.5 or 0.25% levobunolol HC1 at pH 7.2. The sacrifice times were 10 and 30 minutes post-dosing. After animal euthanasia with an intravenous dose of T-61 (American Hoechst Corp., Somerville, NJ), aqueous humor and cornea were collected and assayed for levobunolol and dihydrobunolol.
Two additional groups of eight rabbits were administered one 50 ul dose of the 0.5 % LBUN/4% PILO formulations at pH 5.5 with or without 1.5% Schercopol-CMS. At 15 minutes post-dosing, rabbits were euthanized and cornea and aqueous humor samples collected for drug assay.
HPLC Analysis
Pilocarpine and levobunolol were separately quantified. Levobunolol and dihydrobunolol concentrations in ocular tissues and fluids were measured by an HPLC method with a dual UV/fluoresence detection mode (11). Pilocarpine was quantitated separately using a previously published HPLC method (12). Both methods have welldocumented accuracy, precision, and selectivity (11, 12) . DATA 
ANALYSIS
The distribution coefficient (DC) was the ratio of the drug concentrations in the n-octanol phase and in the aqueous phase. The Setschenow constant (13) (Table I ). The absorption of pilocarpine increased by 50% when the pH in the formulation increased from pH 5.5 to 7.2. The ocular absorption of levobunolol ranged between 0.6 to 1.9% of the dose and was significantly increased when the formulation pH increased from 5.5 to 7.2 and when 4% pilocarpine was removed from the dosage (Table I ). The ocular absorption of levobunolol was lowest among the three solution dosages when the dose contained 4% pilocarpine at pH 5.5. Approximately 40% of the levobunolol dose that was absorbed into the posterior chamber in vitro was (Figure 1) . However, the aqueous humor concentrations of levobunolol and dihydrobunolol after dosing with the 0.5% LBUN/2% PILO pH 5.5 formulation were approximately half of those observed after dosing of the 0.25% LBUN pH 7.2 formulation, indicative of a four-fold reduction in (Table II) . SP-CMS significantly reduced corneal metabolism of levobunolol to dihydrobunolol. The corneal penetration of pilocarpine was not affected by SP-CMS. When ocular absorption of levobunolol was evaluated in vivo, SP-CMS significantly improved the ocular absorption of levobunolol in the cornea and aqueous humor at pH 5.5 ( Figure 3 ).
DISCUSSION
Although drug concentrations in both the cornea and aqueous humor were measured from the in vivo study, aqueous humor data had less variability and were more reliable in predicting ocular absorption of levobunolol. Because the sampling time points were close to the dosing time, it was likely that the corneal surface contained variable amounts of residual drug from the dosages. Therefore, the aqueous humor concentration was a more sensitive indicator of ocular bioavailability than the corneal drug concentations. Our study results demonstrated a four-fold decrease in ocular bioavailability of levobunolol due to the presence of pilocarpine in the same ophthalmic solution. Many combination dosages were developed to improve patient compliance and convenience. In the case of developing a combination dosage for ß-adrenergic antagonist (pka~8 and 9) and pilocarpine, the clinical implications of reduced but not additive therapeutic efficacy should be considered.
